3 Health Product, Boron Chemical and Footwear Stocks With a Strong Future Roadmap: FDC, Indo Borax & Chemicals and Redtape
- October 15, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
FDC Rs 348.55, P/E 18.05. Indo Borax Rs 481.25, P/E 27.49. Redtape Rs 113.46, P/E 25.49. Closing prices of 14 Oct 2026.
Quick Answer
Health product, boron chemical and footwear stocks with the clearest long-term roadmaps today include FDC in oral rehydration products such as Electral along with eye, ear and anti-infective formulations, Indo Borax in boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Redtape in footwear, apparel and accessories sold through its own brand stores and online channels. FY26 revenue growth was 3.9% at FDC, 21.0% at Indo Borax and 17.5% at Redtape. P/E stands at 18.05 for FDC (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 25.49 for Redtape (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Health product, boron chemical and footwear stocks give investors exposure to health products, industrial chemicals and branded footwear. Volumes, pricing and input costs decide how much of that demand turns into profit.
This list covers three health product, boron chemical and footwear stocks: FDC for oral rehydration products such as Electral along with eye, ear and anti-infective formulations, Indo Borax & Chemicals for boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Health Product, Boron Chemical and Footwear Stocks?
Health product, boron chemical and footwear stocks are shares of companies that make health products, chemicals or sell footwear. Results depend on volumes, pricing and input costs, so margins and cash flow separate the stronger names.
Health Product, Boron Chemical and Footwear Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three health product, boron chemical and footwear stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| FDC | 348.55 | 5,281 | 18.05 | 37.59 | 11.32% | 0.01 |
| Indo Borax & Chemicals | 481.25 | 1,548 | 27.49 | 36.60 | 11.09% | 0.00 |
| Redtape | 113.46 | 6,285 | 25.49 | 66.59 | 23.55% | 0.70 |
Among healthcare and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Health Product, Boron Chemical and Footwear Stocks Have a Strong Roadmap in India?
Health product, boron chemical and footwear stocks have a strong roadmap in India because steady health product use, glass and ceramic output and branded footwear demand keep adding volumes for these firms. Three drivers stand out.
- Health products: Oral rehydration and eye care products see steady demand.
- Industrial use: Glass, ceramics and farms use boron chemicals.
- Branded footwear: Shoppers shift towards organised brands.
FDC: Established Brands Drive the Pipeline
FDC’s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.
Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.
Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.
Indo Borax & Chemicals: Boron Chemicals Anchor the Roadmap
Indo Borax’s roadmap rests on boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture, with wide industrial usage supporting volumes.
Revenue grew from Rs 178.93 crore in FY22 to Rs 230.89 crore in FY26, a 29.0% rise, and FY26 revenue was 21.0% higher than FY25. FY26 net profit rose 18.3% to Rs 50.27 crore. Over four years, net profit rose from Rs 36.37 crore in FY22 to Rs 50.27 crore. In Q1 FY27, revenue grew 28.9% to Rs 72.92 crore, and net profit rose 59.3% to Rs 16.25 crore. Operating margin was 27.28% in FY26 and 31.78% in Q1 FY27 against 28.43% a year earlier.
Debt to equity is 0.00 and return on equity is 11.09%. FY26 operating cash flow was Rs 87.15 crore against capital expenditure of Rs 0.29 crore. Indo Borax paid a dividend of Rs 1 per share for FY26, a yield of 0.21%. At a P/E of 27.49 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 31.78% against 27.28% for FY26, so margin stability is the figure to follow as volumes grow.
Redtape: A Footwear Brand Anchors the Roadmap
Redtape’s roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.
FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.
Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.
Best Health Product, Boron Chemical and Footwear Stocks in India: FDC vs Indo Borax vs Redtape on Key Financials
Among the best health product, boron chemical and footwear stocks in India, FDC leads on the lowest P/E; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Redtape leads on FY26 net profit growth and return on equity. The table puts the numbers side by side.
| Metric | FDC | Indo Borax | Redtape |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 2,284.45 | 230.89 | 2,551.61 |
| FY26 revenue growth | 3.9% | 21.0% | 17.5% |
| FY26 net profit (Rs Cr) | 281.42 | 50.27 | 240.55 |
| FY26 net profit growth | 5.5% | 18.3% | 41.5% |
| FY26 operating profit margin | 20.21% | 27.28% | 20.07% |
| Q1 FY27 revenue growth (YoY) | 4.6% | 28.9% | 4.8% |
| Q1 FY27 net profit growth (YoY) | 9.2% | 59.3% | 15.2% |
| Return on equity | 11.32% | 11.09% | 23.55% |
| P/E ratio | 18.05 | 27.49 | 25.49 |
| Debt to equity | 0.01 | 0.00 | 0.70 |
| Dividend yield | 1.54% | 0.21% | 1.76% |
| FY26 operating cash flow (Rs Cr) | 200.45 | 87.15 | 174.01 |
Healthcare, chemicals and consumer earnings follow volumes, pricing and input costs, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Health Product, Boron Chemical and Footwear Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen health product, boron chemical and footwear stocks and shortlist health product, boron chemical and footwear stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these health product, boron chemical and footwear stocks
Risks to Consider Before Investing in Health Product, Boron Chemical and Footwear Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track FDC, Indo Borax and Redtape live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover health products, boron chemicals and footwear. FDC leads on the lowest P/E; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Redtape leads on FY26 net profit growth and return on equity.
Across health product, boron chemical and footwear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the health product, boron chemical and footwear stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Health Product, Boron Chemical and Footwear Stocks
Which are the best health product, boron chemical and footwear stocks in India with a strong roadmap?
Ans. FDC, Indo Borax & Chemicals and Redtape stand out for their roadmaps in health products, boron chemicals and footwear. FY26 revenue growth was 3.9% at FDC, 21.0% at Indo Borax and 17.5% at Redtape, and return on equity ranges from 11.09% to 23.55%.
Is FDC a good stock to buy now?
Ans. FDC has a debt to equity ratio of 0.01, a return on equity of 11.32% and a P/E of 18.05 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of FDC, Indo Borax and Redtape?
Ans. The P/E ratio is 18.05 for FDC (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 25.49 for Redtape (industry 66.59). All of them trade below the industry multiple.
Which of these health product, boron chemical and footwear stocks has the highest return on equity?
Ans. Redtape has the highest return on equity at 23.55%, followed by FDC at 11.32% and Indo Borax & Chemicals at 11.09%.
What are the risks of investing in health product, boron chemical and footwear stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did FDC, Indo Borax and Redtape perform in Q1 FY27?
Ans. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. Indo Borax & Chemicals reported revenue of Rs 72.92 crore, up 28.9% year on year, and net profit rose 59.3% to Rs 16.25 crore. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.
Do health product, boron chemical and footwear stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 1.54% for FDC, 0.21% for Indo Borax and 1.76% for Redtape, based on dividends declared for FY26.
How can I invest in health product, boron chemical and footwear stocks in India?
Ans. You can buy health product, boron chemical and footwear stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.